View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 9, 2018updated 22 Nov 2021 8:37am

Sandoz recalls one batch of hypertension drug over impurity

Novartis unit Sandoz has voluntarily recalled one lot of Losartan Potassium-Hydrochlorothiazide tablets after finding traces of impurity in the API Losartan manufactured by Zhejiang Huahai Pharmaceutical.

Novartis unit Sandoz has voluntarily recalled one lot of Losartan Potassium-Hydrochlorothiazide tablets after finding traces of impurity in the API Losartan manufactured by Zhejiang Huahai Pharmaceutical (ZHP).

The N-nitrosodiethylamine (NDEA) impurity is classified as a potential human carcinogen by the International Agency for Research on Cancer (IARC).

Losartan Potassium-Hydrochlorothiazide tablets are indicated for the treatment of hypertension as a monotherapy or in combination with other antihypertensive agents.

“Patients should contact their physician or healthcare provider if they have experienced any problems.”

Sandoz said that the recalled lot of its products, which are produced by Lek Pharmaceuticals in Slovenia, has so far not led to any adverse event reports.

The company is notifying distributors and retailers and asking them to immediately cease distribution of the identified batch.

It also advised patients to seek alternative therapy before returning their current medication.

Sandoz in a statement said: “Patients who are on Losartan Potassium-Hydrochlorothiazide should continue taking their medication, as the risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.

“Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using Losartan Potassium-Hydrochlorothiazide.”

NDEA was previously discovered by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in September in multiple batches of drugs containing valsartan as the active pharmaceutical ingredient (API).

ZHP reported the presence of this impurity in several batches of its valsartan API. The FDA also found it in three lots of Torrent Pharmaceuticals’ recalled valsartan products.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology